Fate Therapeutics, a biotechnology company, has appointed Christian Weyer as their chief executive.
Takeda-backed biotechnology company, Fate Therapeutics, has appointed Christian Weyer as chief executive. Weyer joins Fate after 12 years spent at biopharmaceutical company Amylin Pharmaceuticals. Fate Therapeutics researches the therapeutic potential of adult stem cell biology.
Fate has also elected William Rastetter to the company’s board of directors, which is effective immediately. Rastetter, a partner at Venrock, has served as Fate’s interim chief executive since November 2011 and will remain chairman of Fate’s board of directors.
Weyer commented on his appointment,…
